https://www.selleckchem.com/products/ezm0414.html
5±2.9% (p0.001), +1.6±2.7% (p0.001) and+1.5±3.9% (p=0.002) in the alendronate group. The spine, but not the hip or femoral neck, BMD at month 12 was significantly higher in the denosumab than alendronate group after adjustment for baseline BMD values, age, sex, osteoporosis risk factors and the cumulative prednisolone doses received in one year. The drop in P1NP and CTX was significantly higher in the denosumab than alendronate group. Frequency of adverse events (AEs), including infections, was similar in the two treatment arms.
Me gusta
Comentario
Compartir
